[go: up one dir, main page]

WO1993014187A1 - Souche bacterienne de l'espece bacillus coagulans et son utilisation comme agent probiotique - Google Patents

Souche bacterienne de l'espece bacillus coagulans et son utilisation comme agent probiotique Download PDF

Info

Publication number
WO1993014187A1
WO1993014187A1 PCT/EP1993/000030 EP9300030W WO9314187A1 WO 1993014187 A1 WO1993014187 A1 WO 1993014187A1 EP 9300030 W EP9300030 W EP 9300030W WO 9314187 A1 WO9314187 A1 WO 9314187A1
Authority
WO
WIPO (PCT)
Prior art keywords
bacterial strain
feedstuff
bacillus coagulans
day
treated
Prior art date
Application number
PCT/EP1993/000030
Other languages
English (en)
Inventor
Annunciata Adami
Valeria Cavazzoni
Original Assignee
Consiglio Nazionale Delle Ricerche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consiglio Nazionale Delle Ricerche filed Critical Consiglio Nazionale Delle Ricerche
Publication of WO1993014187A1 publication Critical patent/WO1993014187A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/07—Bacillus

Definitions

  • the present invention relates to viable bacterial cells that can be used as probiotics.
  • probiotic there is meant a feedstuff supplement consisting of living microbial cells that beneficially influences the animal host, thereby enhancing its intestine microbial equilibrium.
  • the present invention also relates to formulated feedstuff compositions based on said cells. They are sporogenous bacteria, free of pathogenic potency. They have a high thermal stability and can be kept for a long time. They can possibly multiply under aerobic and anaerobic conditions and produce lactic acid and vitamin factors, as well as substances having an antagonistic selective activity to other microorganisms.
  • the invention also relates to the use of said bacteria as single or associated cultures in the zootechnical field, in order to obtain a better physiologic-nutritional attitude of the monogastric or polygastric livestock, thereby achieving a reduction of the common pathologic breeding manifestations, lowered mortality and favourable effects on the animal growth and feedstuff conversion.
  • the above advantages are especially relevant in the early period after the animal birth, when the risks associated with intensive breeding are usually at their highest.
  • microorganisms act through multiple, intercrossing mechanisms, which possibly comprise the supply of certain growth, vitamin and coenzyme factors, enzyme activity as well as factors antagonizing other harmful, putrefying or pathogenic microorganisms.
  • the mentioned mechanisms may also include the role probably played by the production of lactic acid and/or special substances of metabolic origin that have an antitoxin or antimicrobial effect, as well as the positive interferences in the functional reflexes of the digestive system and the interactions with the intestine microflora of the individual animal.
  • Said object has been achieved according to the present invention trough a newly isolated bacterial strain.
  • It is a sporogenous bacterium that was isolated from ensilated fodder, i.e. an acidic environment typical of lactic bacteria.
  • This strain has been found to be free of pathogenicity, facultatively anaerobe, thermophylic and highly heat resistant, acid tolerant and sarcolactic acid producing. It can be taxonomically assigned to the species Bacillus coagulans.
  • a culture of said strain has been deposited under the stipulations of the Budapest
  • the above-mentioned strain can be cultured from a 24 hour slant to be inoculated into a 750 ml conical flask containing 100 ml of the hereinafter described culture medium, which is shaken for about 1 day and consists "in toto" of the inoculum of a prefermenter containing 2 1 of the same medium.
  • this second broth culture is used to inoculate a 20 liter fermenter containing a production culture medium having the following composition (in g/1 of spring water): corn steep liquor 20, yeast extract 5, casein hydrolizate 2, powdered milk whey 3, mono- potassium phosphate 1, spring water to 1000 ml, pH 7; sterilization at 0.75 atm for 20 minutes.
  • the fermentation is to be carried out under the following conditions: temperature 37°C, stirrer speed 350 rpm, aeration 1 v/v/m, control of the possible foam formation by means of a silicone.
  • the separation of the produced cellular biomass is carried out after 18-24 hours of fermentation. There is obtained a biomass yield of 5-6 g (dry basis) per liter of broth culture.
  • the broth culture is centrifuged, washed with spring water, again centrifuged with a physiological solution and then subjected to liophyilization (approxi ⁇ mately, 50% of spores and 50% of cells).
  • the lyophilized biomass is a light, straw-coloured powder containing 50-100 billions cells per gram of lyophilized product (approximately 50% in spore form) .
  • a microbiological control of the lyophilized biomass is a light, straw-coloured powder containing 50-100 billions cells per gram of lyophilized product (approximately 50% in spore form) .
  • the product which can be conveniently homogenized in powder form at the outlet of the liophyli- zation device or later on at the moment of use, is mixed, by means of suitable equipment, with dextrose or corn flour in such a proportion (0.1-1%) as to provide a premix having a concentration of viable cells of
  • the premix can then be added to feedstuff at a ratio resulting in a concentration of viable cells of 0.35-8 x 10 10 /kg of final feed. This corresponds to about 100-1000 mg of lyophilized preparation/kg of diet, depending on the target animal species and the administration period. The concentration can be increased in the case of use for therapeutical purposes.
  • basal diet only b) basal diet supplemented with 100 ppm of Elancoban (coccidiostatic agent); c) basal diet supplemented with 10 ppm of Virginia ycin (auxinic agent); d) basal diet supplented with cells of the bacterial strain of the present invention, added at a rate of
  • the composition of the basal diet was as follows: corn 55, soybean meal 30, meat meal 5, sunflower meal 5, animal fat 2.5, distillers solubles 1.5.
  • the feedstuff was supplemented with vitamins, amino acids, sodium chloride, potassium phosphate and calcium carbonate.
  • the feedstuff and drinking water have been administered "ad libitum" " from the day 0.
  • the animals have been kept from day 0 - o -
  • Average feed conversion ratio ratio of feedstuff intake to weight increase.
  • the average feed conversion ratio has been determined in the various test periods by calculating the ratio between average daily feed consumption and average daily weight increase.
  • the mortality due to various factors was 4% for the groups a) and d), i.e. the control group and the group feed on a diet containing cells of the bacterial strain according the present invention, respectively. It was 12% for the groups b) and c). The remaining subjects did not show any particular sign of pain in any of the test groups.
  • the weight of the control group was always significantly lower than the weight of the three groups treated with food additives, the group treated with the bacterium included.
  • the average weight and the related percent increase of these groups were: 2403.9 g and 8.8% for the group b), treated with the coccidiostatic agent; 2373.1 g and 7.4% for the group c), treated with Virginiamycin; 2368.8 g and 7.2% for the group d) treated with the bacterium according to the invention.
  • the control group during the whole test period had an average feed conversion ratio higher than the three treated groups, including the bacterium treated group, i.e. a lower conversion of feedstuff into live weight.
  • the groups c) and d) fed on the diet with the added Virginiamycin and the bacterium according to the invention, respectively, had a lower average feed conversion ratio in the first three weeks, i.e. a better conversion of feedstuff into live weight as compared with the coccidiostat-treated group. It is to be noted that the animals treated with the bacterium exhibited a lower average feed conversion ratio until the end of the test.
  • the average feed conversion ratio of the control group was 2.07; the average feed conversion ratio and the corresponding percent improvement relative to the control group were: 1.98 and 4.6% for the coccidiostatic agent-treated group; 2.00 and 3.5% for the Virginiamycin-treated group; 1.95 and 6.1% for the group treated with the present bacterium, which is the best result.
  • the treatment based on the use of the bacterium of the present invention results in a growth promoting effect that can fully substitute the common practice based on sub-therapeutical doses of an antibiotic additive such as Virginiamycin, since it exhibits the same effectiveness for the weight increase and conversion of feedstuff into live weight of the animal.
  • Half-breed Landrace Large White piglets have been used. Seven farrows with a total of 56 piglets have been considered ( 8 animals, total 32, for the group treated with a growth promoting agent, taken as the control, and 3 8 animal, total 24, for the piglets treated with the bacterium of the present invention), and followed from weaning (day 30) for more than 5 weeks.
  • the treated group was fed, after weaning, with feedstuff, medicated with only Tylosine for the prophylaxis of respiratory diseases, supplemented with 4 x 10 10 CFU/kg of feedstuff for the first seven days and with 1 x 10 10 CFU/kg of feedstuff for the other four weeks.
  • control groups were fed with the same feedstuff as used for the treated animals, but supplemented with Carbadox, a chemoprofilactic agent used as a growth promoter, instead of the bacterial biomass.
  • the weight has been monitored at days 0 (weaning day), 27 and 35.
  • a feedstuff based on low fat (60%) milk supplemented with cells of the bacterial strain of the present invention.
  • the amount of feedstuff and the concentration were such that the dosis of bacterial strain was 4 x 10 10 CFU / animal / day for 4 days, until the age of seven days, and 1 x 10 10 CFU / animal / day as from the seventh day of life.
  • the intervention at the maximum foreseen dosis has indicated a certain activity which can also be interpreted as a therapeutic activity attributable to the described bacterial strain.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Husbandry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Fodder In General (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Nouvelle souche de bactéries sporogènes imputable à l'espèce Bacillus coagulans et utilisable comme additif pour les aliments destinés aux animaux. On décrit le procédé de préparation à la fois des cultures et des compositions alimentaires formulées dans lesquelles on utilise lesdites bactéries.
PCT/EP1993/000030 1992-01-14 1993-01-09 Souche bacterienne de l'espece bacillus coagulans et son utilisation comme agent probiotique WO1993014187A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI920042A IT1262927B (it) 1992-01-14 1992-01-14 Batteri sporgenti e loro impiego come probiotici
ITMI92A00042 1992-01-14

Publications (1)

Publication Number Publication Date
WO1993014187A1 true WO1993014187A1 (fr) 1993-07-22

Family

ID=11361527

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1993/000030 WO1993014187A1 (fr) 1992-01-14 1993-01-09 Souche bacterienne de l'espece bacillus coagulans et son utilisation comme agent probiotique

Country Status (5)

Country Link
AU (1) AU3348693A (fr)
IT (1) IT1262927B (fr)
MX (1) MX9300131A (fr)
WO (1) WO1993014187A1 (fr)
ZA (1) ZA93110B (fr)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998047374A1 (fr) * 1997-04-18 1998-10-29 Ganeden Biotech, Inc. Utilisation topique de spores de bacilles probiotiques pour prevenir ou traiter les infections microbiennes
WO2000007606A3 (fr) * 1998-08-07 2000-05-18 Ganeden Biotech Inc Procedes mettant en oeuvre des bacteries probiotiques non productrices d'acide lactique pour augmenter la solubilite de substances nutritives
WO2000010582A3 (fr) * 1998-08-24 2000-07-13 Ganeden Biotech Inc Bacteries probiotiques produisant de l'acide lactique et leurs utilisations
AU750136B2 (en) * 1997-06-03 2002-07-11 Ganeden Biotech, Inc. Probiotic lactic acid bacterium to treat bacterial infections associated with SIDS
US6531126B2 (en) 1999-08-26 2003-03-11 Ganeden Biotech, Inc. Use of emu oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications and preparations
JP2003513649A (ja) * 1999-11-08 2003-04-15 ガネデン バイオテック， インコーポレイテッド Ｂａｃｉｌｌｕｓｃｏａｇｕｌａｎｓによる病原体の阻害
US6645506B1 (en) 1997-04-18 2003-11-11 Ganeden Biotech, Inc. Topical compositions containing extracellular products of Pseudomonas lindbergii and Emu oil
WO2004080200A1 (fr) * 2003-03-11 2004-09-23 Inatech International Inc. Micro-organismes probiotiques et leurs utilisations
US6811786B1 (en) 1999-04-01 2004-11-02 Ganeden Biotech, Inc. Methods for reducing cholesterol using Bacillus coagulans spores, systems and compositions
US6849256B1 (en) 1999-11-08 2005-02-01 Ganeden Biotech Incorporated Inhibition of pathogens by probiotic bacteria
EP1719518A1 (fr) 1998-08-07 2006-11-08 Ganeden Biotech, Inc. Compositions comprenant bacillus coagulans pour augmenter la solubilité des minéraux
US7507402B1 (en) 1997-04-18 2009-03-24 Ganeden Biotech, Inc. Topical use of probiotic Bacillus spores to prevent or control microbial infections
US7700093B2 (en) 2003-12-05 2010-04-20 Ganeden Biotech, Inc. Methods for increasing lactose digestion
RU2439145C2 (ru) * 2006-12-08 2012-01-10 Тарту Юликоол (Юниверсити Оф Тарту) Штамм микроорганизма bacillus smithii tbmi12 mscl p737 и применение его в качестве пищевой или кормовой добавки, или компонента пробиотической композиции и пробиотическая композиция
KR101357118B1 (ko) * 2011-10-04 2014-02-06 (주)한국바이오케미칼 대추추출물을 이용한 안정성이 개선된 생균제
US8821854B2 (en) 1997-04-18 2014-09-02 Ganeden Biotech, Inc. Methods for inhibiting microbial infections associated with sanitary products and for enhancing sanitary product degradation
WO2015061755A1 (fr) * 2013-10-25 2015-04-30 Phibro Animal Health Corporation Combinaison et/ou composition comprenant des bactéries du genre bacillus et du yucca, du quillaja ou les deux, et procédé de préparation et d'utilisation correspondant
US9446111B2 (en) 2009-04-29 2016-09-20 Ganeden Biotech, Inc. Inactivated bacterial cell formulation
US9622502B2 (en) 2008-10-16 2017-04-18 Ganeden Biotech, Inc. Probiotic Bacillus pasta compositions
US9855288B2 (en) 2007-05-11 2018-01-02 Mannatech, Incorporated Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same
US10383342B2 (en) 2007-08-29 2019-08-20 Ganeden Biotech, Inc. Baked goods
US11235008B2 (en) 2011-03-31 2022-02-01 Ganeden Biotech, Inc. Probiotic sports nutrition compositions

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY110183A (en) * 1992-08-18 1998-02-28 Novartis Ag Process for the preparation of n, n''-substituted ureas
CN102250817A (zh) * 2011-07-21 2011-11-23 北京金泰得生物科技股份有限公司 一株饲用凝结芽孢杆菌及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1204017A (en) * 1968-10-11 1970-09-03 Sankyo Co Animal feed compositions
DE1692490A1 (de) * 1965-10-23 1971-08-05 Sankyo Co Tierische Futterkomposition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1692490A1 (de) * 1965-10-23 1971-08-05 Sankyo Co Tierische Futterkomposition
GB1204017A (en) * 1968-10-11 1970-09-03 Sankyo Co Animal feed compositions

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009269922A (ja) * 1997-04-18 2009-11-19 Ganeden Biotech Inc 微生物感染を予防または制御するための共生Ｂａｃｉｌｌｕｓ芽胞の局所的使用
US8821854B2 (en) 1997-04-18 2014-09-02 Ganeden Biotech, Inc. Methods for inhibiting microbial infections associated with sanitary products and for enhancing sanitary product degradation
US6645506B1 (en) 1997-04-18 2003-11-11 Ganeden Biotech, Inc. Topical compositions containing extracellular products of Pseudomonas lindbergii and Emu oil
JP2002512615A (ja) * 1997-04-18 2002-04-23 ガネデン バイオテック，インコーポレイテッド 微生物感染を予防または制御するための共生Ｂａｃｉｌｌｕｓ芽胞の局所的使用
US7507402B1 (en) 1997-04-18 2009-03-24 Ganeden Biotech, Inc. Topical use of probiotic Bacillus spores to prevent or control microbial infections
US7807185B2 (en) 1997-04-18 2010-10-05 Ganeden Biotech, Incorporated Methods of inhibiting growth of bacteria, yeast, fungus, and virus with Pseudomonas lindbergii and Bacillus coagulans extracellular products
US7541042B2 (en) 1997-04-18 2009-06-02 Ganeden Biotech, Inc. Topical compositions containing Bacillus coagulans extracellular products and uses thereof
US6905692B2 (en) 1997-04-18 2005-06-14 Ganeden Biotech, Inc. Topical compositions containing probiotic bacillus bacteria, spores, and extracellular products and uses thereof
WO1998047374A1 (fr) * 1997-04-18 1998-10-29 Ganeden Biotech, Inc. Utilisation topique de spores de bacilles probiotiques pour prevenir ou traiter les infections microbiennes
US7544363B2 (en) 1997-04-18 2009-06-09 Ganeden Biotech, Inc. Topical compositions containing Bacillus coagulans extracellular products and uses thereof
US6723326B1 (en) 1997-04-18 2004-04-20 Ganeden Biotech, Inc. Topical compositions containing probiotic Bacillus bacteria, spores, and extracellular products and uses thereof
AU750136B2 (en) * 1997-06-03 2002-07-11 Ganeden Biotech, Inc. Probiotic lactic acid bacterium to treat bacterial infections associated with SIDS
JP2002522393A (ja) * 1998-08-07 2002-07-23 ガネデン バイオテック， インコーポレイテッド 共生乳酸産生細菌を使用する、栄養材料の溶解度を増大するための方法
US8273346B2 (en) 1998-08-07 2012-09-25 Ganeden Biotech, Inc. Method for increasing fructose digestion with strains of Bacillus coagulans and fructase
EP1719518A1 (fr) 1998-08-07 2006-11-08 Ganeden Biotech, Inc. Compositions comprenant bacillus coagulans pour augmenter la solubilité des minéraux
US9220736B2 (en) 1998-08-07 2015-12-29 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
WO2000007606A3 (fr) * 1998-08-07 2000-05-18 Ganeden Biotech Inc Procedes mettant en oeuvre des bacteries probiotiques non productrices d'acide lactique pour augmenter la solubilite de substances nutritives
US7767203B2 (en) 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
US8343484B2 (en) 1998-08-07 2013-01-01 Ganeden Biotech, Inc. Methods for increasing lactose and fructose digestion
US8697055B2 (en) 1998-08-24 2014-04-15 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria
JP2002523372A (ja) * 1998-08-24 2002-07-30 ガネデン バイオテック， インコーポレイテッド 共生乳酸産生細菌およびその使用
US8187590B2 (en) 1998-08-24 2012-05-29 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
US8097247B2 (en) 1998-08-24 2012-01-17 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
WO2000010582A3 (fr) * 1998-08-24 2000-07-13 Ganeden Biotech Inc Bacteries probiotiques produisant de l'acide lactique et leurs utilisations
US7807151B2 (en) 1998-08-24 2010-10-05 Ganeden Biotech, Incorporated Probiotic, lactic acid-producing bacteria and uses thereof
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
US7708988B2 (en) 1998-08-24 2010-05-04 Ganeden Biotech, Incorporated Probiotic, lactic acid-producing bacteria and uses thereof
US8349337B1 (en) 1999-04-01 2013-01-08 Ganeden Biotech, Inc. Methods for reducing cholesterol using Bacillus coagulans spores, systems and compositions
US6811786B1 (en) 1999-04-01 2004-11-02 Ganeden Biotech, Inc. Methods for reducing cholesterol using Bacillus coagulans spores, systems and compositions
US7232571B2 (en) 1999-04-01 2007-06-19 Ganeden Biotech, Inc. Methods for reducing cholesterol using Bacillus coagulans spores, systems and compositions
US6531126B2 (en) 1999-08-26 2003-03-11 Ganeden Biotech, Inc. Use of emu oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications and preparations
US7371407B2 (en) 1999-08-26 2008-05-13 Ganeden Biotech, Inc. Use of Emu Oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications and preparations
US6733751B2 (en) 1999-08-26 2004-05-11 Ganeden Biotech, Inc. Use of Emu Oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications & preparations
US7048950B2 (en) 1999-08-26 2006-05-23 Ganeden Biotech, Inc. Use of Emu Oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications and preparations
US6849256B1 (en) 1999-11-08 2005-02-01 Ganeden Biotech Incorporated Inhibition of pathogens by probiotic bacteria
US7713726B2 (en) 1999-11-08 2010-05-11 Ganeden Biotech Incorporated Inhibition of pathogens by probiotic bacteria
US8277799B2 (en) 1999-11-08 2012-10-02 Ganeden Biotech, Incorporated Inhibition of pathogens by probiotic bacteria
JP2003513649A (ja) * 1999-11-08 2003-04-15 ガネデン バイオテック， インコーポレイテッド Ｂａｃｉｌｌｕｓｃｏａｇｕｌａｎｓによる病原体の阻害
WO2004080200A1 (fr) * 2003-03-11 2004-09-23 Inatech International Inc. Micro-organismes probiotiques et leurs utilisations
US7700093B2 (en) 2003-12-05 2010-04-20 Ganeden Biotech, Inc. Methods for increasing lactose digestion
US10111916B2 (en) 2003-12-05 2018-10-30 Ganeden Biotech, Inc. Compositions comprising Bacillus coagulans spores and whey
RU2439145C2 (ru) * 2006-12-08 2012-01-10 Тарту Юликоол (Юниверсити Оф Тарту) Штамм микроорганизма bacillus smithii tbmi12 mscl p737 и применение его в качестве пищевой или кормовой добавки, или компонента пробиотической композиции и пробиотическая композиция
US9855288B2 (en) 2007-05-11 2018-01-02 Mannatech, Incorporated Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same
US10117884B2 (en) 2007-05-11 2018-11-06 Mannatech, Inc. Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same
US10383342B2 (en) 2007-08-29 2019-08-20 Ganeden Biotech, Inc. Baked goods
US10321704B2 (en) 2008-10-16 2019-06-18 Ganeden Biotech, Inc. Probiotic grain-based compositions
US9622502B2 (en) 2008-10-16 2017-04-18 Ganeden Biotech, Inc. Probiotic Bacillus pasta compositions
US11419355B2 (en) 2008-10-16 2022-08-23 Ganeden Biotech, Inc. Probiotic grain-based compositions
US9757442B2 (en) 2009-04-29 2017-09-12 Ganeden Biotech, Inc. Inactivated bacterial cell formulation
US9446111B2 (en) 2009-04-29 2016-09-20 Ganeden Biotech, Inc. Inactivated bacterial cell formulation
US11235008B2 (en) 2011-03-31 2022-02-01 Ganeden Biotech, Inc. Probiotic sports nutrition compositions
US11351206B2 (en) 2011-03-31 2022-06-07 Ganeden Biotech, Inc. Probiotic sports nutrition compositions
KR101357118B1 (ko) * 2011-10-04 2014-02-06 (주)한국바이오케미칼 대추추출물을 이용한 안정성이 개선된 생균제
US9999648B2 (en) 2013-10-25 2018-06-19 Phibro Animal Health Corporation Combination and/or composition comprising bacillus, and yucca, quillaja, or both and a method for using and making
WO2015061755A1 (fr) * 2013-10-25 2015-04-30 Phibro Animal Health Corporation Combinaison et/ou composition comprenant des bactéries du genre bacillus et du yucca, du quillaja ou les deux, et procédé de préparation et d'utilisation correspondant
US10660930B2 (en) 2013-10-25 2020-05-26 Phibro Animal Health Corporation Combination and/or comprising bacillus, and yucca, quillaja, or both and a method for using and making

Also Published As

Publication number Publication date
AU3348693A (en) 1993-08-03
IT1262927B (it) 1996-07-22
ITMI920042A0 (it) 1992-01-14
MX9300131A (es) 1994-07-29
ITMI920042A1 (it) 1993-07-14
ZA93110B (en) 1993-07-14

Similar Documents

Publication Publication Date Title
US20240389620A1 (en) Feed additive composition
WO1993014187A1 (fr) Souche bacterienne de l'espece bacillus coagulans et son utilisation comme agent probiotique
US10398156B2 (en) Animal feed compositions and feed additives
Jadhav et al. Probiotics in broiler poultry feeds: A review
CN101220342B (zh) Fq15粪肠球菌以及采用该菌种生产促生长饲料添加剂的方法
Ayasan et al. The effects of dietary inclusion of probiotic protexin on egg yield parameters of Japanese quails (Coturnix coturnix Japonica)
US20040175372A1 (en) Novel lactobacillus reuteri useful as probiotics
RU2412612C1 (ru) Способ получения пробиотической кормовой добавки ферм км для сельскохозяйственных животных и птицы
US20170042949A1 (en) System and method for production of shelf stable probiotics for animal nutrition enhancement
CN101165162A (zh) 一种益生菌活性制剂
EP1611796B1 (fr) Composition alimentaire
US11382940B2 (en) Lactobacillus salivarius CJLS1511, animal feed additive composition comprising same bacterium or dead cells thereof, and method for producing same dead cells
WO1993002558A1 (fr) Procede et formulation servant a reduire des populations microbiennes
WO2008091137A1 (fr) Additifs antibiotiques d'aliments pour animaux comportant un extrait d'éthanol de larves de mouche domestique comme principe actif et son procédé de fabrication
JPS62104552A (ja) 飼料組成物
KR101580616B1 (ko) 내산성, 내담즙산성 및 항균 활성을 갖는 바실러스 메틸로트로피쿠스 c14 균주 및 이의 용도
CA2100774C (fr) Additif pour l'alimentation animale
CN110419622B (zh) 一种复合益生菌寡糖水果饲料添加剂及其制备使用方法
KR880001275B1 (ko) 동물 사료의 제조방법
CN106036082B (zh) 一种抗猪腹泻的无抗饲料
CN106520614A (zh) 一种利用产中性蛋白酶的凝结芽孢杆菌提高北京油鸡生产性能的方法
Shome et al. Effect of probiotics on performance of native chicken of Andaman
JP2000325027A (ja) 増体促進剤
Jawad et al. Iraqi Probiotic
HK1240778A1 (en) Animal feed compositions and feed additives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA HU JP PL RU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA